Inhibitory effect of fucoidan on the activities of crotaline snake venom myotoxic phospholipases A2

Biochemical Pharmacology

Volumn 66, Issue 10, 2003, Pages 1993-2000

  Angulo, Yamileth ^a   Lomonte, Bruno ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Fucoidan; Inhibition; Myotoxin; Phospholipase A2; Polysaccharide; Snake venom

Indexed keywords

ATROPOIDES NUMMIFER MYOTOXIN 1; ATROPOIDES NUMMIFER MYOTOXIN 2; BOTHRIECHIS SCHLEGELLI MYOTOXIN 1; BOTHROPS ASPER MYOTOXIN 1; BOTHROPS ASPER MYOTOXIN 2; BOTHROPS ASPER MYOTOXIN 3; BOTHROPS ASPER MYOTOXIN 4; CERROPHIDION GODMANI MYOTOXIN 1; CERROPHIDION GODMANI MYOTOXIN 2; FUCOIDIN; PHOSPHOLIPASE A2; SNAKE VENOM; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROTECTION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENVENOMATION; ENZYME INHIBITION; FUCUS VESICULOSUS; MEMBRANE DAMAGE; MOUSE; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE TOXICITY; NONHUMAN; PRIORITY JOURNAL; SEAWEED; TOXICITY; TURBIDIMETRY;

EID: 0242266592     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00579-3     Document Type: Article

References (53)

1. 2 enzymes. Prostagl. Lipid Med. 68/69:2002;3-58.
2. Rosenberg P. Phospholipases. In: Shier WT, Mebs D, editors. Handbook of toxinology. New York: Marcel Dekker; 1990. p. 67-277.
3. 2 from Bothrops asper snake venom: synthetic Lys49 myotoxin II-(115-129)-peptide identifies its bactericidal region. Eur. J. Biochem. 253:1998;452-461.
4. Campbell JA, Lamar WW. The venomous reptiles of Latin America. New York: Cornell University Press; 1989. p. 1-425.
5. Gutiérrez JM. Clinical toxicology of snakebite in Central America. In: Meier J, White J, editors. Handbook of clinical toxicology of animal venoms and poisons. Boca Raton, FL: CRC Press; 1995. p. 645-65.
6. Mebs D., Ownby C.L. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacol. Ther. 48:1997;223-236.
7. 2 enzymes: structure, function, and mechanism. Chichester: Wiley; 1997. p. 321-52.
8. 2 isozyme genes. Proc. Natl. Acad. Sci. U.S.A. 92:1995;5605-5609.
9. Soares A.M., Rodrigues V.M., Homsi-Brandeburgo M.I., Toyama M.H., Lombardi F.R., Arni R.K., Giglio J.R. A rapid procedure for the isolation of the Lys-49 myotoxin II from Bothrops moojeni (caissaca) venom: biochemical characterization, crystallization, myotoxic and edematogenic activity. Toxicon. 36:1998;503-514.
10. 2 from the venoms of rattlesnakes and other pit vipers. Archs. Biochem. Biophys. 394:2001;236-244.
11. 2 enzymes: classification and characterization. Biochim. Biophys. Acta. 1488:2000;1-19.
12. 2 isozymes. FEBS Lett. 429:1998;385-389.
13. 2 myotoxins from its own venom: isolation, molecular cloning, and biological properties. Biochem. J. 346:2000;631-639.
14. Rocha S.L.G., Lomonte B., Neves-Ferreira A.G.C., Trugilho M.R.O., Junqueira de Azevedo I.L.M., Ho P.L., Domont G., Gutiérrez J.M., Perales J. Functional analysis of DM64, an antimyotoxic protein with immunoglobulin-like structure from Didelphis marsupialis serum. Eur. J. Biochem. 269:2002;6052-6062.
15. Deepa M., Gowda T.V. Purification and characterization of a glycoprotein inhibitor of toxic phospholipase from Withania somnifera. Archs. Biochem. Biophys. 408:2002;42-50.
16. Arruda E.Z., Silva N.M.V., Moraes R.A.M., Melo P.A. Effect of suramin on myotoxicity of some crotalid snake venoms. Braz. J. Med. Biol. Res. 35:2002;723-726.
17. Melo P.A., Homsi-Brandeburgo M.I., Giglio J.R., Suarez-Kurtz G. Antagonism of the myotoxic effect of Bothrops jararacussu venom and bothropstoxin by polyanions. Toxicon. 31:1993;285-291.
18. 2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family. Biochem. Pharmacol. 47:1994;1509-1518.
19. 2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J. Biol. Chem. 269:1994;29867-29873.
20. Patankar M., Oehninger S., Barnett T., Williams R., Clark G. A revised structure for fucoidan may explain some of its biological activities. J. Biol. Chem. 268:1993;21770-21776.
21. Nishino T., Nishioka C., Ura H., Nagumo T. Isolation and partial characterization of a novel amino sugar-containing fucan sulfate from commercial Fucus vesiculosus fucoidan. Carbohydr. Res. 255:1994;213-223.
22. Preobrazhenskaya M.E., Berman A.E., Mikhailov V.I., Ushakova N.A., Mazurov A.V., Semenov A.V., Usov A.I., Nifantev N.E., Bovin N.Y. Fucoidan inhibits leukocyte recruitment in a model peritoneal inflammation in rat and blocks interaction of P-selectin with its carbohydrate ligand. Biochem. Mol. Biol. Int. 43:1997;443-451.
23. Luyt C.E., Meddahi-Pelle A., Ho-Tin-Noe B., Colliec-Jouault S., Guezennec J., Louedec L., Prats H., Jacob M.P., Osborne-Pellegrin M., Letourneur D., Michel J.B. Low-molecular weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J. Pharmacol. Exp. Ther. 305:2003;24-30.
24. Durig J., Bruhn T., Zurborn K.H., Gutensohn K., Bruhn H.D., Beress L. Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb. Res. 85:1997;479-491.
25. Fujimura T., Shibuya Y., Moriwaki S., Tsukahara K., Kitahara T., Sano T., Nishizawa Y., Takema Y. Fucoidan is the active component of Fucus vesiculosus that promotes contraction of fibroblast-populated collagen gels. Biol. Pharm. Bull. 23:2000;1180-1184.
26. Religa P., Kazi M., Thyberg J., Gaciong Z., Swedenborg J., Hedin U. Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity. Eur. J. Vas. Endovasc. Surg. 20:2000;419-426.
27. Church F.C., Meade J.B., Treanor R.E., Whinna H.C. Antithrombin activity of fucoidan. J. Biol. Chem. 264:1989;3618-3623.
28. Minix R., Doctor V.M. Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis. Thromb. Res. 87:1997;419-429.
29. Koyanagi S., Tanigawa N., Nakagawa H., Soeda S., Shimeno H. Oversulfation of fucoidan enhances its antiangiogenic and antitumor activities. Biochem. Pharmacol. 65:2003;173-179.
30. Zapopozhets T.S., Besednova N.N., Loenko I.N. Antibacterial and immunomodulating activity of fucoidan. Antibiot. Khimioter. 40:1995;9-13.
31. Gutiérrez J.M., Ownby C.L., Odell G.V. Isolation of a myotoxin from Bothrops asper venom: partial characterzation and action on skeletal muscle. Toxicon. 22:1984;115-128.
32. Lomonte B., Gutiérrez J.M. A new muscle damaging toxin, myotoxin II, from the venom of the snake Bothrops asper (terciopelo). Toxicon. 27:1989;725-733.
33. Kaiser I.I., Gutiérrez J.M., Plummer D., Aird S.D., Odell G.V. The amino acid sequence of a myotoxic phospholipase from the venom of Bothrops asper. Arch. Biochem. Biophys. 278:1990;319-325.
34. 2 variant, from Bothrops asper snake venom. Nat. Toxins. 3:1994;26-31.
35. 2 from Bothrops godmani (Godman's pit viper) snake venom. Arch. Biochem. Biophys. 298:1992;135-142.
36. Gutiérrez J.M., Lomonte B., Cerdas L. Isolation and partial characterization of a myotoxin from the venom of the snake Bothrops nummifer. Toxicon. 24:1986;885-894.
37. 2 homologue. Int. J. Biochem. Cell Biol. 32:2000;63-71.
38. 2 from the venom of the arboreal snake Bothriechis (Bothrops) schlegelii from Costa Rica. Archs. Biochem. Biophys. 339:1997;260-266.
39. Traub P., Mizushima S., Lowry C.V., Nomura M. Reconstitution of ribosomes from subribosomal components. Meth. Enzymol. 20:1971;391-417.
40. 2 on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells in vitro. Toxicon. 37:1999;145-158.
41. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon. 39:2001;1587-1594.
42. 2 from snake venoms. Toxicon 2003, in press.
43. Dole V.P. Relation between nonesterified fatty acids in plasma and the metabolism of glucose. J. Clin. Invest. 35:1956;150-154.
44. 2 from Bothrops asper snake venom. Arch. Biochem. Biophys. 358:1998;343-350.
45. Mahanta M., Mukherjee A.K. Neutralisation of lethality, myotoxicity and toxic enzymes of Naja kaouthia venom by Mimosa pudica root extracts. J. Ethnopharm. 75:2001;55-60.
46. 2 with lysine in place of aspartate 49. J. Biol. Chem. 259:1984;13839-13843.
47. 2. J. Biol. Chem. 261:1986;4797-4804.
48. 2. Biochem. J. 366:2002;971-976.
49. 2 from snake venoms. Toxicon 2003, in press.
50. Mourão P.A.S., Pereira M. Searching for alternatives to heparin: sulfated fucans from marine invertebrates. Trends Cardiovasc. Med. 9:1999;225-232.
51. 2 from the venom of the snake Bothrops asper by monoclonal antibodies. Toxicon. 30:1992;239-245.
52. 2 from Bothrops pirajai snake venom. Arch. Biochem. Biophys. 387:2001;188-196.
53. Lomonte B., Lundgren J., Johansson B., Bagge U. The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study. Toxicon. 32:1994;41-55.